EXPANDNCT06956014
Efficacy and Safety of VER-01 in the Treatment of Participants With Chronic Painful Lumbosacral Radiculopathy
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 10 versions: 10 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 40 → 43 locations
- Trial sites expanded: 32 → 40 locations
- Minor Study sites: 32 to 40
- Minor Trial sites expanded: 22 → 32 locations
- Minor Trial sites expanded: 1 → 22 locations
- Minor Study sites: 1 to 22
- Notable Recruitment opened
- Eligibility criteria expanded, about 6 words
- Study sites: 0 to 1
- Start date changed from estimate of Sep 2026 to Sep 22, 2026
- Notable Primary and study completion pushed from Nov 2027 to Sep 2028
- Eligibility criteria shortened, about 80 words
- Study title shortened, about 1 word
Notable Start date: Mar 2026 to Sep 2026v3 Show 4 more changesShow less
- Eligibility criteria expanded, about 16 words
- Enrollment target: 700 to 810
- Primary and study completion dates: Sep 2027 to Nov 2027
- Study title expanded, about 1 word
- Notable Start date: Nov 2025 to Mar 2026
- Primary and study completion dates: May 2027 to Sep 2027
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Efficacy based on pain reduction
Timeframe: From Baseline to Treatment Week 12
Arms and interventions
VER-01 Dose 1Experimental
VER-01 Dose 2Experimental
PlaceboPlacebo comparator
Drugs: VER-01
Other: Placebo
Sites
43 sites in 1 country